Large-cap Technology company Vertex Pharmaceuticals has moved -1.7% so far today on a volume of 1,253,071, compared to its average of 971,895. In contrast, the S&P 500 index moved 0.0%.
Vertex Pharmaceuticals trades -2.42% away from its average analyst target price of $388.67 per share. The 24 analysts following the stock have set target prices ranging from $315.0 to $456.0, and on average have given Vertex Pharmaceuticals a rating of buy.
If you are considering an investment in VRTX, you'll want to know the following:
-
Vertex Pharmaceuticals's current price is 188.4% above its Graham number of $131.52, which implies that at its current valuation it does not offer a margin of safety
-
Vertex Pharmaceuticals has moved 24.0% over the last year, and the S&P 500 logged a change of 15.0%
-
Based on its trailing earnings per share of 13.3, Vertex Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of 28.5 while the S&P 500 average is 15.97
-
VRTX has a forward P/E ratio of 23.4 based on its forward 12 month price to earnings (EPS) of $16.22 per share
-
The company has a price to earnings growth (PEG) ratio of 2.45 — a number near or below 1 signifying that Vertex Pharmaceuticals is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 6.32 compared to its sector average of 6.23
-
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
-
Based in Boston, the company has 4,800 full time employees and a market cap of $97.88 Billion.